What Is MOTS-c? Everything You Should Know Before Starting

MOTS-c at a glance:

• Drug class: Mitochondrial-derived peptide
• Route: subcutaneous injection in research
• Typical frequency: varies
• Half-life: minutes systemically

Let's cut through the marketing on MOTS-c and look at what the data actually say. MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, and the result for users is: improved insulin sensitivity, exercise capacity, and metabolic flexibility in rodent models.

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It activates AMPK, improves insulin sensitivity, and influences metabolic homeostasis in animal studies.

There is no single FDA-licensed manufacturer of MOTS-c for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. MOTS-c is not currently approved by the FDA for general human use. Available evidence comes from animal and cell-culture studies. We do not endorse self-administration of unapproved compounds.

The drug class mitochondrial-derived peptide works by targeting specific receptor pathways. Here's how that breaks down.

How MOTS-c Works in the Body

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It activates AMPK, improves insulin sensitivity, and influences metabolic homeostasis in animal studies. The receptor target — compound-specific — drives the downstream effects users care about: improved insulin sensitivity, exercise capacity, and metabolic flexibility in rodent models.

The pharmacokinetics matter for daily use. MOTS-c has a half-life of minutes systemically, which determines how often it is dosed. The standard route of administration is subcutaneous injection in research, and the typical schedule is varies.

For more detail on the underlying biology, see our breakdown of how MOTS-c works.

Who Uses MOTS-c?

MOTS-c is most relevant for people whose situation maps to its approved indications: none — investigational.

People who should avoid MOTS-c include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of MOTS-c include:

• limited human data

Serious risks — uncommon but worth knowing — include:

• unknown long-term

We have a more detailed breakdown in our MOTS-c side-effects guide.

MOTS-c vs Alternatives

Approved insulin-sensitizing therapies include metformin and pioglitazone. If you are weighing MOTS-c against another option, our comparison pages include What Nobody Tells You About MOTS-c Side Effects, MOTS-c Outcomes Decoded: Who Responds Best and Why, How Much Does MOTS-c Really Cost? The Honest Breakdown.

Bottom Line

If you're considering MOTS-c, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering MOTS-c, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• What Nobody Tells You About MOTS-c Side Effects
• MOTS-c Outcomes Decoded: Who Responds Best and Why
• How Much Does MOTS-c Really Cost? The Honest Breakdown
• MOTS-c Cycle and Protocol: What Researchers Actually Use
• NAD+ 101: A Plain-English Guide for 2026
• NAD+ Side Effects Decoded: What's Normal vs. What Isn't

Sources

• Birk AV et al. The Mitochondrial-Targeted Peptide SS-31 Selectively Improves Mitochondrial Function. JASN 2013;24:1250.
• Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015;21:443.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.